| Name | Title | Contact Details |
|---|
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
BLDG is a creative refuge for design, branding, and all things art and culture. We create, we collaborate, we party. Seek the refuge.
Simility helps companies prevent fraud and abuse with machine learning, big data analytics and data visualization capabilities. Simility levels the playing field against even the most sophisticated fraud ring by enabling analysts to create and configure detection mechanisms without having to write one line of code. Free to analyze trends and test insights at will, analysts can now match fraudsters move for move.
MediKeeper is a San Diego, CA-based company in the Software and Internet sector.